Lutetium Lu 177 DOTA-Tetulomab

Preferred Label : Lutetium Lu 177 DOTA-Tetulomab;

NCIt synonyms : 177Lu-HH1; 177Lu-Dota-Tetulomab; 177Lu-DOTA-HH1;

NCIt related terms : TETULOMAB TETRAXETAN LU-177;

NCIt definition : A radioimmunoconjugate, which consists of a monoclonal antibody against the cell-surface antigen CD37 covalently linked, via the bifunctional, macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA), to the beta-emitting radioisotope lutetium Lu 177, with potential antineoplastic activity. The antibody moiety of lutetium Lu 177 DOTA-tetulomab binds to CD37 on tumor B-cells. Upon internalization, the radioisotope moiety delivers a cytotoxic dose of beta radiation to CD37-expressing tumor cells. CD37, a transmembrane glycoprotein, is overexpressed in B-cell malignancies.;

UNII : CPW7BR9UY7;

Details

Origin ID

C105403;

UMLS CUI

C4519092;

Currated CISMeF NLP mapping
- Lilotomab satetraxetan (177-Lu) (substance) [SNOMED CT concept]
- tetulomab tetraxetan lu-177 [MeSH Supplementary Concept]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Indicator, Reagent, or Diagnostic Aid [UMLS semantic type]
UMLS correspondences (same concept)
- Lilotomab satetraxetan (177-Lu) (substance) [SNOMED CT concept]
- tetulomab tetraxetan lu-177 [MeSH Supplementary Concept]
concept_is_in_subset
- CTRP Agent Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- GDC Value Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
has_target
- Leukocyte Antigen CD37 [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients